medigraphic.com
ISSN 0185-3252 (Impreso)
Revista de la Asociación Médica del Centro Médico ABC

2000, Número 4

<< Anterior Siguiente >>

An Med Asoc Med Hosp ABC 2000; 45 (4)


Quimioterapia en cáncer germinal y epitelial de ovario

Gerson R, Serrano A, Villalobos A

Idioma: Español
Referencias bibliográficas: 54
Paginas: 193-199
Archivo PDF: 63.53 Kb.


RESUMEN

Genéricamente, el cáncer de ovario representa enfermedades con comportamientos clínicos distintos. Así, los tumores poco frecuentes de células germinales son tratados con éxito en la gran mayoría de las pacientes, mediante regímenes convencionales de quimioterapia. En contraste, en el cáncer epitelial, que representa el 90% de los casos, a pesar de que muestra sensibilidad a la quimioterapia, no se ha logrado alcanzar resultados satisfactorios. En la búsqueda de mejores respuestas para el tratamiento de la neoplasia epitelial de ovario, recientemente se han investigado nuevos fármacos como paclitaxel, doxorrubicina liposomal, docetaxel, topotecan, gemcitabina y combinaciones de diferentes drogas, así como tratamientos con base en anticuerpos monoclonales que ofrecen una nueva esperanza. El objetivo de este trabajo es revisar y difundir las tácticas de tratamiento citotóxico disponibles para esta neoplasia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Secretaría de Salud. Registro Histopatológico de Neoplasias en México. Departamento de Epidemiología de la Secretaría de Salud. 1996: 3-12.

  2. Gershenson DM, Kavanaugh JJ, Copeland LJ et al. Treatment of malignant non disgerminomatous germ cell tumors of the ovary vith vinblastine, bleomycin and cisplatin. Cancer 1986; 57: 1731-1737.

  3. Gajewski W, Legare RD. Ovarian Cancer. Surg Oncol Clin North Am 1998; 7 (2): 17-33.

  4. Williams SD. Germ cell tumors: Hemat/Oncol Clin North Am 1992; 6: 967-974.

  5. Gerson R, García Irigoyen C, García González H et al. Quimioterapia en cáncer testicular de alto riesgo. Experiencia en el grupo uro-oncológico del Hospital General SS (1976-1990). Rev Med Hosp Gen Mex 1993; 56: 66-74.

  6. Williams SD. Ovarian germ cell tumors: An update. Sem Oncol 1998; 25 (3): 407-13.

  7. Slayton RE, Park RC, Silverberg SG et al. Vincristine, dactinomicin and cyclophosphamide in the treatment of malignant germ-cell tumors of the ovary: a gynecologic/oncologic group of study. Cancer 1985; 56: 243-248.

  8. Williams SD, Blessing JA, Moore DH et al. Cisplatin, Vinblastine and bleomycin in recurrent ovarian germ cell tumors. Ann Int Med 1989; 11: 22-27.

  9. Gershenson DM. Menstrual and reproductive function after treatment with combination for malignant ovarian germ cell tumors. J Clin Oncol 1988; 6: 270-275.

  10. Abu-Rustum NR, Aghajanian C. Management of malignat germ cell tumors of the ovary. Sem Oncol 1998; 25 (2): 235-42.

  11. Ozols RF. Chemotherapy for advanced epithelial ovarian cancer. Hemat/Oncol Clin North Am 1992; 6: 879-894.

  12. Neijt JR. Treatment of advanced ovarian cancer; 10 years of experience. Ann Oncol 1992; 3: 17-27.

  13. Swenerton KD, Hislop TG, Spinelly J et al. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obster Gynecol 1985; 65: 264-69.

  14. De Souza PL, Fredlander ML. Prognostic factors in ovarian cancer. Hematol/Oncol Clin North Am 1992; 6: 761-781.

  15. Klein B, Folkson G, Smit CF. Advanced ovarian carcinoma. Factor influencing survival. Cancer 1985; 55: 1829-1834.

  16. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Symposium on ovarian carcinoma. Nat Cancer Inst Monog 1975; 42: 101-104.

  17. Ozols RF, Rubin SC, Denbo AS et al. Epithelial ovarian cancer, in Hoskins WJ; JP Lippincot, Philadelphia 1992: 731-782.

  18. Levin L, Hryniuck WM. Doses intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756-767.

  19. Ozols RF. Ovarian cancer treatment. Curr Prob Cancer 1992; 16: 67-126.

  20. Ozols RF. Carboplatin and paclitaxel in ovarian cancer. Sem Oncol 1995; 22 (3): 78-83.

  21. ten Bokkel Huinik WW, Vander Burg MEL, van Ooosterom AT et al. Carboplatin in combination in therapy for ovarian cancer. Cancer Treat Rev 1988; 15: 9-15.

  22. Ozols RF. Treatment of ovarian cancer: Current status. Sem Oncol 1994; 21 (2): 1-9.

  23. Haisworth JD, Grosh WW, Burnett LS et al. Advanced ovarian cancer: Long-term results of treatment with intensive cisplatin based chemotherapy of brief duration. Ann Inter Med 1988; 108: 165-170.

  24. Ozols RF, Ostchega Y, Curt G et al. High dose carboplatin in refractary ovarian cancer patients. J Clin Oncol 1987; 5: 197-201.

  25. Bertelsen K, Jacobsen A, Andersen JE et al. A randomized study of cyclophosphamide and cisplatin with or without doxorubicin in advanced ovarian cancer. Gynecol Oncol 1987; 28: 161-169.

  26. Markman M. Rationale for examining the combination of paclitaxel and Ifosfamide in the treatment of advanced ovarian cancer. Sem Oncol 1995; 22 (3): 88-89.

  27. Gershenson DM, Kavannaugh JJ, Coppeland LJ et al. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin based chemotherapy. Obstet Gynecol 1989; 73: 798-801.

  28. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.

  29. Sabbatini P, Spriggs D. Salvage therapy of ovarian cancer. Oncology 1998; 12 (6): 833-843.

  30. Caldas C, William P, McGuire III. Taxol in epithelial ovarian cancer. Monogr Natl Cancer Inst 1993; 15: 155-159.

  31. Gerson R, Serrano A, Villalobos A et al. Toxicidad con paclitaxel en infusión de 24 horas. Rev Inst Nac Cancerología 1995; 41: 215-221.

  32. Reed E, Kohn EC, Sarosy G et al. Paclitaxel, carboplatin and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Sem Oncol 1995; 22 (3): 90-96.

  33. Schink JC. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Sem Oncol 1999; 26 (supl 1): 2-7.

  34. McGuire WP, Ozols RE. Chemotherapy of advanced ovarian cancer. Sem Oncol 1998; 25 (6): 340-8.

  35. McGuire WP, Hoskins WJ, Brady MF et al. Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer (AOC) as compared to cytoxan and cisplatin (CP). Proc ASCO 1995; 14: 771 (abstract).

  36. ten Bokkel Huinink W, Veenhof C, Helmerhorst T et al. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Sem Oncol 1995; 22 (3): 97-100.

  37. Markman M. Intraperitoneal therapy of ovarian cancer. Sem Oncol 1998; 25(3): 356-60.

  38. Markman M, Francis P, Rowinsky E, Hoskins W. Intraperitoneal paclitaxel: a possible role in management of ovarian cancer? Sem Oncol 1995; 22 (3): 84-87.

  39. Piccart MJ, Gore M, ten Bokkel Huinink W et al. Docetaxel: an active new drug for the treatment for advanced epithelial ovarian cancer. J Natl Can Inst 1995; 87 (9): 676-681.

  40. Kemp GM, Glover TJ, Shein PS. The role of WR-27-21 in the reduction of combined cisplatine and cyclophosphamide toxicity. Proc ASCO 1990; 9: 67, 259.

  41. Herrin VE, Thigpen JT. High-dose chemotherapy in ovarian carcinoma. Sem Oncol 1999; 26 (supl 1): 99-105.

  42. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancer. Drugs 1997; 54 (supl 4): 22-29.

  43. McGuire WP III. Epithelial ovarian cancer. ASCO, Educational Book, 2000: 541-546.

  44. Hensley M, Hoope B, Leon L et al. Clinical use of liposomal doxorrubicin in platinum refractory ovarian cancer: predictors of response in pre-treated patients. Proc ASCO 2000; 1555: 393.

  45. Kaye SB. Gemcitabine: Current status of phase I and II trials. J Clin Oncol 1994; 12 (8): 1527-1531.

  46. Millward MJ, Rischin D, Toner GC et al. Activity of gemcitabine in ovarian cancer patients resistant to paclitaxel. Proc ASCO 1995; 14 776: 277.

  47. Rowinsky EK, Verweij J. Review of phase I clinical studies with topotecan. Sem Oncol 1997; 24 supl. 20: 3-10.

  48. Kollmannsberger C, Mross K, Jakob A et al. Topotecan- A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 1999; 56 (1): 1-12.

  49. Coleman RL, Miller DS. Topotecan in the treatment of gynecologic cancer. Sem Oncol 1997; 24 supl. 20: 55-63.

  50. Arbuck SG, Takimoto CH. An overview of topoisomerase I targeting agents. Sem Hematol 1998; 35 (supl 4): 3-12.

  51. Hofstra LS, Bos M, de Vries EG et al. Intraperitoneal topotecan with standard IV carboplatin and paclitaxel in ovarian cancer is feasible. Proc ASCO 2000; 1548: 391.

  52. Mutto MG, Kassis AJ. Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Cancer 1995; 76: 2016-2027.

  53. Kosmas C, Epenetos AA, Courtenay-Luck NS. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 1994; 73: 3000-3010.

  54. Gomez-Navarro J, Siegal GP, Alvarez RD et al. Gene therapy: ovarian cancer as the paradigm. Am J Clin Pathol 1998; 109 (4): 444-467.




2020     |     www.medigraphic.com